Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP), the pharmaceutical company developing prescription cannabinoid medicines, is pleased to announce its final results for the year ended 30 April 2023 (the "Period") ("Final Results"), as well as the filing of its Annual Report and Accounts.
Commenting on the results, Julie Pomeroy, OCTP Non-Executive Chair, said:
"This has been a defining year for Oxford Cannabinoid Technologies, marked by a number of major milestones and significant achievements. The dedication, expertise and relentless pursuit of excellence by our team has delivered the transition of OCT from pre-clinical stage to a clinical-stage pharmaceutical company. We have seen two of our programmes complete their pre-clinical stages during the year with one of them moving into a Phase I clinical trial in Q2 2023 and are well-positioned for future clinical developments."
Read the full story here.
Date posted: 31 August 2023
Article tag: Oxford Cannabinoid Technologies
Share